Erlangen Experiences with Durvalumab Preservation Therapy after defnitive Radiochemotherapy in Patients with NSCLC: First Survival and Toxicity Data from clinical Routine
Lettmaier S, Hecht M, Fietkau R (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: SPRINGER HEIDELBERG
City/Town: HEIDELBERG
Pages Range: S87-S87
Conference Proceedings Title: STRAHLENTHERAPIE UND ONKOLOGIE
Event location: Weisbaden
Authors with CRIS profile
How to cite
APA:
Lettmaier, S., Hecht, M., & Fietkau, R. (2020). Erlangen Experiences with Durvalumab Preservation Therapy after defnitive Radiochemotherapy in Patients with NSCLC: First Survival and Toxicity Data from clinical Routine. In STRAHLENTHERAPIE UND ONKOLOGIE (pp. S87-S87). Weisbaden, DE: HEIDELBERG: SPRINGER HEIDELBERG.
MLA:
Lettmaier, Sebastian, Markus Hecht, and Rainer Fietkau. "Erlangen Experiences with Durvalumab Preservation Therapy after defnitive Radiochemotherapy in Patients with NSCLC: First Survival and Toxicity Data from clinical Routine." Proceedings of the 26th Annual Conference of the German-Society-for-Radiation-Oncology (DEGRO), Weisbaden HEIDELBERG: SPRINGER HEIDELBERG, 2020. S87-S87.
BibTeX: Download